PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsAcute coronary syndrome
MeSH D054058 - acute coronary syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D017202:Myocardial ischemia
0 Companies
0 Drugs
Success rate
D054058: 
Acute coronary syndrome
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareRivaroxaban Rivaroxaban Accord  2020-11-16   
AstraZenecaTicagrelor Brilique  2010-12-03   
Ticagrelor Possia  2010-12-03   
Bristol Myers SquibbClopidogrel Clopidogrel BMS  2008-07-16   
Chiesi FarmaceuticiCangrelor Kengrexal  2015-03-23   
KrkaClopidogrel Zyllt  2009-09-28   
MylanClopidogrel, Acetylsalicylic acid Clopidogrel / Acetylsalicylic acid Mylan  2020-01-09   
Prasugrel Prasugrel Mylan  2018-05-15   
Rivaroxaban Rivaroxaban Viatris (previously Rivaroxaban Mylan)  2021-11-12   
SanofiClopidogrel, Acetylsalicylic acid Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)  2010-03-14   
Clopidogrel, Acetylsalicylic acid DuoPlavin  2010-03-14   
Clopidogrel Iscover  1998-07-14   
Clopidogrel Plavix  1998-07-15   
SubstipharmPrasugrel Efient  2009-02-24   
TevaClopidogrel Clopidogrel Teva (hydrogen sulphate)  2009-07-27   
Clopidogrel Clopidogrel ratiopharm  2015-02-18   
Clopidogrel, Acetylsalicylic acid Clopidogrel/Acetylsalicylic acid Teva  2014-09-01   
Clopidogrel Clopidogrel Teva Generics B.V  2010-10-28   
Clopidogrel Clopidogrel Teva Pharma B.V  2011-06-16   
The Medicines CompanyBivalirudin Angiox  2004-09-20   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
69%
18/26
Phase 2
73%
24/33
Phase 3
61%
31/51
Approved: 5Overall Success rate: 31%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AstraZeneca
Chiesi Farmaceutici
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use